Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Total raised

$83M

Funding rounds

1

Latest round

Series A

Latest activity

May 2026